Company Filing History:
2 out of 53 
2 out of 19 
2 out of 2 Years Active: 2010-2012
Title: The Innovative Contributions of Ulla M Wewer in Medical Science
Introduction: Ulla M Wewer, an accomplished inventor based in Klampenborg, Denmark, has made significant strides in the field of medical diagnostics. With two patents to his name, Wewer has focused on developing tools that enhance the understanding and identification of abnormal cell functions, particularly in pregnancy-related conditions.
Latest Patents: Ulla M Wewer's latest patent, pertaining to ADAM12, highlights a groundbreaking approach to detecting abnormal cell function. This invention provides a method, an assay, and a kit designed to offer insights into the presence of abnormal cellular activity. Notably, Wewer demonstrated that changes in serum ADAM12 concentrations could serve as a prognostic tool, predicting clinical outcomes, complications, and mortality associated with abnormal cell function. The invention identifies ADAM12 as a general marker for various fetal chromosomal diseases and placental dysfunctions, making it particularly valuable for assessing conditions such as Down's syndrome, trisomy 18, preeclampsia, and Turner syndrome during both the first and second trimesters. Wewer's work also includes the development of enzyme-linked immunosorbent assays (ELISA) and time-resolved immunofluorometric assays that quantify ADAM12 levels in serum, further establishing its clinical relevance.
Career Highlights: Ulla M Wewer has accrued valuable experience while working with prestigious institutions such as Statens Serum Institut and Københavns Universitet. His dedication to advancing medical knowledge and diagnostics has positioned him as a thought leader in his domain.
Collaborations: Throughout his career, Wewer has collaborated with notable professionals such as Michael Christiansen and Jennie Laigaard. These partnerships have fueled innovation and contributed to the successful development of diagnostic tools tailored to enhance patient outcomes.
Conclusion: Ulla M Wewer's innovative contributions, particularly in the realm of abnormal cell function markers, reflect his commitment to improving medical diagnostics. His patents, notably regarding ADAM12, stand as a testament to his skill and determination, underscoring the potential for scientific advancements to impact healthcare positively.